The role of ERK1/2 signaling pathway in coronary microembolization-induced rat myocardial inflammation and injury

Cardiology

Volumn 117, Issue 3, 2011, Pages 207-215

  Li, Lang ^a   Li, Dong Hua ^a   Qu, Nan ^a   Wen, Wei Ming ^a   Huang, Wie Qiang ^a  

^a Medical University   (China)

Author keywords

Coronary microembolization; Extracellular signal regulated kinases 1 2; Inflammation; Myocardial; Tumor necrosis factor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY EMBOLISM; ARTICLE; ARTIFICIAL EMBOLISM; CONTROLLED STUDY; CORONARY MICROEMBOLIZATION; CYTOKINE PRODUCTION; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GEL MOBILITY SHIFT ASSAY; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HEART MUSCLE INJURY; IMMUNOHISTOCHEMISTRY; MALE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, FAR-WESTERN; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CORONARY OCCLUSION; DISEASE MODELS, ANIMAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIUM; PHOSPHORYLATION; PLAQUE, ATHEROSCLEROTIC; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649782403     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321713     Document Type: Article

References (44)

1. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1-e157.
2. Heusch G, Kleinbongard P, Böse D, Levkau B, Haude M, Schulz R, Erbel R: Coronary microembolization: from bedside to bench and back to bedside. Circulation 2009; 120: 1822-1836.
3. Nassenstein K, Breuckmann F, Bucher C, Kaiser G, Konorza T, Schäfer L, Konietzka I, de Greiff A, Heusch G, Erbel R, Barkhausen J: How much myocardial damage is necessary to enable detection of focal late gadolinium enhancement at cardiac MR imaging? Radiology 2008; 249: 829-835.
4. Carlsson M, Wilson M, Martin AJ, Saeed M: Myocardial microinfarction after coronary microembolization in swine: MR imaging Characterization. Radiology 2009; 250: 703-713.
5. Dörge H, Neumann T, Behrends M, Skyschally A, Schulz R, Kasper C, Erbel R, Heusch G: Perfusion-contraction mismatch with coronary microvascular obstruction: role of inflammation. Am J Physiol Heart Circ Physiol 2000; 279:H2587-H2592.
6. Carlsson M, Ursell PC, Saloner D, Saeed M: Magnetic resonance imaging quantification of left ventricular dysfunction following coronary microembolization. Magn Reson Med 2009; 61: 595-602.
7. Carlsson M, Saloner D, Martin AJ, Ursell PC, Saeed M: Heterogeneous microinfarcts caused by coronary microemboli: evaluation with multidetector CT and MR imaging in a swine model. Radiology 2010; 254: 718-728.
8. Dicks DL, Carlsson M, Heiberg E, Martin A, Saloner D, Arheden H, Saeed M: Persistent decline in longitudinal and radial strain after coronary microembolization detected on velocity encoded phase contrast magnetic resonance imaging. J Magn Reson Imag 2009; 30: 69-76.
9. Thielmann M, Dorge H, Martin C, Belosjorow S, Schwanke U, van de Sand A, Konietzka I, Büchert A, Krüger A, Schulz R, Heusch G: Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-α, and sphingosine. Circ Res 2002; 90: 807-813.
10. Skyschally A, Haude M, Dörge H, Thielmann M, Duschin A, van de Sand A, Konietzka I, Büchert A, Aker S, Massoudy P, Schulz R, Erbel R, Heusch G: Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. Circulation 2004; 109: 2337-2342.
11. Dörge H, Schulz R, Belosjorow S, Post H, van de Sand A, Konietzka I, Frede S, Hartung T, Vinten-Johansen J, Youker KA, Entman ML, Erbel R, Heusch G: Coronary microembolization: the role of TNF-α in contractile dysfunction. J Mol Cell Cardiol 2002; 34: 51-62.
12. Michel MC, Li Y, Heusch G: Mitogen-activated protein kinases in the heart. Naunyn Schmiedebergs Arch Pharmacol 2001; 363: 245-266.
13. Heidbreder M, Naumann A, Tempel K, Dominiak P, Dendorfer A: Remote vs. ischaemic preconditioning: the differential role of mitogen-activated protein kinase pathways. Circ Res 2008; 78: 108-115.
14. Mizukami Y, Ono K, Du CK, Aki T, Hatano N, Okamoto Y, Ikeda Y, Ito H, Hamano K, Morimoto S: Identification and physiological activity of survival factor released from cardiomyocytes during ischaemia and reperfusion. Circ Res 2008; 79: 589-599.
15. Tutor AS, Penela P, Mayor F Jr: Anti-beta1- adrenergic receptor autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells. Circ Res 2007; 76: 51-60.
16. Lv X WJ, Yang J, Cheng H, Li Y, Ao Y, Peng R: Cytochrome P450 omega-hydroxylase inhibition reduces cardiomyocyte apoptosis via activation of ERK1/2 signaling in rat myocardial ischemia-reperfusion. Eur J Pharmacol 2008; 596: 118-126.
17. Mizukami Y IA, Aki T, Kimura M, Nakamura K, Nao T, Okusa T, Matsuzaki M, Yoshida K, Kobayashi S: ERK1/2 regulates intracellular ATP levels through alpha-enolase expression in cardiomyocytes exposed to ischemic hypoxia and reoxygenation. J Biol Chem 2004; 279:50120-50131.
18. Sawatzky DA, Willoughby DA, Colville- Nash PR, Rossi AG: The involvement of the apoptosis-modulating proteins ERK 1/2, Bcl-xL and Bax in the resolution of acute inflammation in vivo. Am J Pathol 2006; 168: 33-41.
19. Demyanets S, Kaun C, Rychli K, Rega G, Pfaffenberger S, Afonyushkin T, Bochkov VN, Maurer G, Huber K, Wojta J: The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways. Am J Physiol Heart Circ Physiol 2007; 293:H1962-H1968.
20. Lee PJ, Zhang X, Shan P, Ma B, Lee CG, Homer RJ, Zhu Z, Rincon M, Mossman BT, Elias JA: ERK1/2 mitogen-activated protein kinase selectively mediates IL-13-induced lung inflammation and remodeling in vivo. J Clin Invest 2006; 116: 163-173.
21. Kalenikova EI, Gorodetskaya EA, Zacharova NV, Shechter AB, Medvedev OS: Perindopril effects on angiotensin I elimination in lung after experimental myocardial injury induced by intracoronary microembolization in rats. J Cardiovasc Pharmacol 1998; 32: 608-615.
22. Wang C, Weihrauch D, Schwabe DA, Bienengraeber M, Warltier DC, Kersten JR, Pratt PF Jr, Pagel PS: Extracellular signalregulated kinases trigger isoflurane preconditioning concomitant with upregulation of hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in rats. Anesth Analg 2006; 103: 281-288.
23. Falk E: Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983; 50: 127-134.
24. Bahrmann P, Werner GS, Heusch G, Ferrari M, Poerner TC, Voss A, Figulla HR: Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions. Circulation 2007; 115: 600-608.
25. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, Matsui H, Toki Y, Ito T, Hayakawa T: Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1202-1209.
26. Bolognese L, Carrabba N, Santoro GM, Valenti R, Buonamici P, Antoniucci D: Angiographic findings, time course of regional and global left ventricular function, and clinical outcome in diabetic patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty. Am J Cardiol 2003; 91: 544-549.
27. Porto I, Selvanayagam JB, Van Gaal WJ, Prati F, Cheng A, Channon K, Neubauer S, Banning AP: Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation 2006; 114: 662-669.
28. Jaffe R, Charron T, Puley G, Dick A, Strauss BH: Microvascular obstruction and the noreflow phenomenon after percutaneous coronary intervention. Circulation 2008; 117: 3152-3156.
29. Lorenz K, Schmitt JP, Schmitteckert EM, Lohse MJ: A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med 2009; 15: 75-83.
30. Maillet M, Purcell NH, Sargent MA, York AJ, Bueno OF, Molkentin JD: DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility. J Biol Chem 2008; 283: 31246-31255.
31. Rossi F, Castelli A, Bianco MJ, Bertone C, Brama M, Santiemma V: Ghrelin induces proliferation in human aortic endothelial cells via ERK1/2 and PI3K/Akt activation. Peptides 2008; 29: 2046-2051.
32. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY: Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Circ Res 2009; 81: 370-380.
33. Adya R, Tan BK, Punn A, Chen J, Randeva HS: Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Circ Res 2008; 78: 356-365.
34. Lv X, Wan J, Yang J, Cheng H, Li Y, Ao Y, Peng R: Cytochrome P450 omega-hydroxylase inhibition reduces cardiomyocyte apoptosis via activation of ERK1/2 signaling in rat myocardial ischemia-reperfusion. Eur J Pharmacol 2008; 596: 118-126.
35. Mizukami Y, Iwamatsu A, Aki T, Kimura M, Nakamura K, Nao T, Okusa T, Matsuzaki M, Yoshida K, Kobayashi S: ERK1/2 regulates intracellular ATP levels through α-enolase expression in cardiomyocytes exposed to ischemic hypoxia and reoxygenation. J Biol Chem 2004; 279: 50120-50131.
36. Lazou A, Iliodromitis EK, Cieslak D, Voskarides K, Mousikos S, Bofilis E, Kremastinos DT: Ischemic but not mechanical preconditioning attenuates ischemia/reperfusion induced myocardial apoptosis in anaesthetized rabbits: the role of Bcl-2 family proteins and ERK1/2. Apoptosis 2006; 11: 2195-2204.
37. Skyschally A, Leineweber K, Gres P, Haude M, Erbel R, Heusch G: Coronary microembolization. Basic Res Cardiol 2006; 101: 373-382.
38. Lawrence MC, Jivan A, Shao C, Duan L, Goad D, Zaganjor E, Osborne J, McGlynn K, Stippec S, Earnest S, Chen W, Cobb MH: The roles of MAPKs in disease. Cell Res 2008; 18: 436-442.
39. Takahashi K, Fukushima S, Yamahara K, Yashiro K, Shintani Y, Coppen SR, Salem HK, Brouilette SW, Yacoub MH, Suzuki K: Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart. Circulation 2008; 118:S106-S114.
40. Seger R, Krebs EG: The MAPK signaling cascade. FASEBJ J 1995; 9: 726-735.
41. Caunt CJ, Finch AR, Sedgley KR, McArdle CA: Seven-transmembrane receptor signalling and ERK compartmentalization. Trends Endocrinol Metabol 2006; 17: 276-283.
42. Baud V, Karin M: Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001; 11: 372-377.
43. Goetze S, Xi XP, Kawano Y, Kawano H, Fleck E, Hsueh WA, Law RE: TNF-α -induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension 1999; 33: 183-189.
44. Moon SK, Cha BY, Kim CH: ERK1/2 mediates TNF-α -induced matrix metalloproteinase- 9 expression in human vascular smooth muscle cells via the regulation of NF-κ B and AP-1: involvement of the RAS dependent pathway. J Cell Physiol 2004; 198: 417-427.